Search clinical trials for: HTD4010

Total 6 results

HighTide Biopharma Pty Ltd

Completed

Study of HTD4010 in Healthy Volunteers

Type 2 Diabetes Mellitus

Australia
Suven Life Sciences Limited

Completed

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects

Cognitive Disorder

United States
Suven Life Sciences Limited

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Cognitive Disorders

United States
Transgene
Bristol-Myers Squibb

Completed

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer Metastatic

Hungary, France, United States, Belgium
Karen Kelly
Bristol-Myers Squibb; National Cancer Institute (NCI); Transgene

Completed

TG4010 and Nivolumab in Patients With Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
Transgene

Terminated

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME)

Non-Small-Cell Lung Carcinoma

United States, France, Hungary, United Kingdom, Spain, Israel, Belgium, Germany, Poland, Italy

3

Subscribe